Mekasermin
| Klinički podaci | |
|---|---|
| Prodajno ime | Increlex, Increlex (Tercica), Iplex |
| Drugs.com | Monografija |
| Način primene | Subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 2 h |
| Identifikatori | |
| CAS broj | 68562-41-4  |
| ATC kod | H01AC03 (WHO) |
| DrugBank | DB01277 |
| ChEMBL | CHEMBL1201716 |
| Hemijski podaci | |
| Formula | C331H512N94O101S7 |
| Molarna masa | 7648.67 |
Mekasermin INN, Increlex) je rekombinantni ljudski insulinu sličan faktor rasta 1 (IGF-I), koji se koristi kao dugoročni tretman neuspešnog rasta kod dece sa jakom deficijencijom primarnog IGF-I.[1][2] IGF-1 se sastoji od 70 aminokiselina u jednom lancu sa tri intramolekulska disulfidna mosta i molekulskom težinom od 7649 Daltona.[3][4][5][6][7][8][9]
Reference
[уреди | уреди извор]- ^ Fintini, D; Brufani, C; Cappa, M (2009). „Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency”. Therapeutics and Clinical Risk Management. 5 (3): 553—9. PMC 2724186
. PMID 19707272.
- ^ „Increlex”. Drugs.com. Приступљено 10. 1. 2010.
- ^ Keating GM. Keating, Gillian M. (2008). „Mecasermin”. BioDrugs. 22 (3): 177—88. PMID 18481900. doi:10.2165/00063030-200822030-00004.
- ^ Rosenbloom AL. Rosenbloom, Arlan L. (2009 Jan). „Mecasermin (recombinant human insulin-like growth factor I)”. Adv Ther. 26 (1): 40—54. PMID 19198769. doi:10.1007/s12325-008-0136-5. Проверите вредност парамет(а)ра за датум:
|date=(помоћ) Jan 28. - ^ Kemp SF. „Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options”. BioDrugs. 23 (3): 155—63. 2009. PMID 19627167. doi:10.2165/00063030-200923030-00002...
- ^ Rosenbloom AL. „Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet”. 368 (9535). август 2006: 612—6. PMID 16905026.
- ^ Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL. Lewis, Michael E.; Neff, Nicola T.; Contreras, Patricia C.; Stong, David B.; Oppenheim, Ronald W.; Grebow, Peter E.; Vaught, Jeffry L. (новембар 1993). „Insulin-like growth factor-I: potential for treatment of motor neuronal disorders”. Exp Neurol. 124 (1): 73—88. PMID 8282084. doi:10.1006/exnr.1993.1177.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
